康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 01-15 16:00:00 EST

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO/wiki","defaultTab":"wiki","newsList":[{"id":"2590393913","title":"招银国际：2025医保目录公布延续支持创新 料CXO业下半年修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393913","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590393913?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:03","pubTimestamp":1765245827,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，2025年版基本医保目录以及首版商保目录发布，延续支持创新，料CXO行业有望在下半年迎来业绩修复。推荐买入三生制药(01530)、固生堂(02273)、药明合联(02268)、巨子生物(02367)、信达生物(01801)、中国生物制药(01177)。报告表示，多家企业的核心创新品种获纳入医保。该行认为，宏观环境及老龄化的挑战下，医保收支压力仍在，关注国家集采续约。尽管首版商保目录短期对于产品销售的拉动有限，由于商业保险的规模不大，认为商保目录的意义重大，或将开启中国商业医疗保险扩容的道路，成为中国多元化支付体系发展开端。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU0502904849.HKD","LU2097828714.EUR","02273","BK1219","02367","LU0455707207.USD","IE00BZ08YT58.USD","BK1583","01801","LU2097828474.EUR","LU2097828805.USD","BK1207","01530","SG9999004311.SGD","BK1141","BK1161","BK1589","LU2328871848.SGD","BK1521","HK0000165453.HKD","IE00BZ08YR35.GBP","02268","LU2097828557.USD","01177","BK1593","SG9999014674.SGD","LU2488822045.USD","CXO","BK1515","LU1969619763.USD","LU2242644610.SGD","IE00BZ08YS42.EUR","LU2097828631.EUR"],"gpt_icon":0},{"id":"2585363594","title":"港股概念追踪|创新药企业绩普遍增长  上游CXO行业调整基本完成（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2585363594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585363594?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:12","pubTimestamp":1763943133,"startTime":"0","endTime":"0","summary":"国际化驱动创新药企业业绩增长，位于创新药产业链上游，被称为行业“卖铲人”的CXO板块，也迎来了需求增长，从而推动业绩整体增长。从整体来看，当前创新药产业正迎来政策推动、需求爆发的双重利好，二者正共同激活新药研发需求，并进一步传导至产业链上游的CXO板块。CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","02269","BK1589","BK1574","LU1046422090.SGD","LU0456827905.SGD","159992","BK1521","LU1880383366.USD","LU0823426308.USD","LU1242518857.USD","LU0140636845.USD","LU0979878070.USD","LU0516423091.SGD","LU1688375341.USD","LU2045819591.USD","LU0039217434.USD","LU0051755006.USD","LU2242644610.SGD","LU0348825331.USD","02359","LU0181495838.USD","LU0417516902.SGD","BK1191","BK1610","LU0052750758.USD","LU0417516738.SGD","LU0326950275.SGD","LU3063872942.SGD","LU2039709279.SGD","LU1794554557.SGD","LU0823426480.USD","SG9999002463.SGD","LU0708995583.HKD","06978","LU0516422366.SGD","BK1576","CXO","LU0359202008.SGD","IE00B0JY6N72.USD","LU2125910500.SGD","06821","BK1161","SG9999002562.SGD","LU0819121731.USD","LU1242518931.SGD","BK1583","LU0348735423.USD","LU0043850808.USD","BK1141"],"gpt_icon":0},{"id":"2585435821","title":"中信建投：CXO行业调整基本完成 重点关注出海能力强的CDMO企业及临床CRO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585435821?lang=zh_cn&edition=full","pubTime":"2025-11-24 07:36","pubTimestamp":1763940962,"startTime":"0","endTime":"0","summary":"CXO行业调整基本完成，海外需求稳定，国内投融资触底回升，重点关注出海能力强的CDMO企业及临床CRO龙头。从国际比较优势看，中国具备人口与内需优势、制造与供应链优势，同时创新能力快速提升，中国资产出海数量也持续提升。2025年下半年我们重点关注的是药品和耗材集采政策优化、多元化支付及医疗服务价格改革。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601066","BK4139","CXO","CDMO","BK0276"],"gpt_icon":0},{"id":"2585448396","title":"海纳医药转战港股IPO背后：CXO依赖症、现金流失血、大客户频变","url":"https://stock-news.laohu8.com/highlight/detail?id=2585448396","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585448396?lang=zh_cn&edition=full","pubTime":"2025-11-23 15:28","pubTimestamp":1763882880,"startTime":"0","endTime":"0","summary":"　　冲刺A股创业板折戟、被上市公司成都先导并购未果后，近日南京海纳医药科技股份有限公司递交招股书转道港股市场，开启三年内的第三次资本化尝试。　　证券之星注意到，这家号称“药物技术转移CXO服务排名第二”的公司，正面临经营性现金流转负、应收账款激增，毛利率承压的多重考验。这背后，海纳医药高度依赖CXO业务，陷入“增收不增利”困境，频繁变动的大客户更凸显业务结构的不稳定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-11-23/doc-infykswe4862812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1515","CXO","159938","09939","159399","BK1161"],"gpt_icon":0},{"id":"2583554140","title":"新股前瞻|港股再迎CXO新势力，海纳医药“含金量”几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554140","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554140?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:21","pubTimestamp":1763022073,"startTime":"0","endTime":"0","summary":"近日，据港交所披露，南京海纳医药科技股份有限公司向港交所主板提交上市申请书，中金公司为其独家保荐人。截至2025年上半年末，海纳医药仍有398个正在进行的CXO项目。除CXO服务外，海纳医药还拥有自主立项的专有管线。于往绩记录期间，海纳医药签订了67份药物技术转让协议。尽管具有一定的成长性，但与国内聚焦创新药的CXO龙头企业相比，海纳医药主要布局仿制药领域，技术门槛相对较低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","BK1574","159938","BK1161","CXO"],"gpt_icon":0},{"id":"2582323536","title":"海纳医药港股IPO：上半年收入、净利润双下滑业绩增长乏力 高度依赖CXO服务 \"多次开发\"模式可持续性存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2582323536","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582323536?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:06","pubTimestamp":1762934760,"startTime":"0","endTime":"0","summary":"南京海纳医药科技股份有限公司于2025年11月7日正式向港交所递交主板上市申请，这是公司继2023年创业板IPO折戟和2025年与成都先导并购谈判失败后，三年内第三次尝试登陆资本市场。　　作为一家成立24年的医药研发与制造一体化企业，海纳医药凭借“CXO+MAH”业务模式在细分领域占据一席之地。　　海纳医药的营收增长已显疲态。　　海纳医药的收入严重依赖CXO服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-12/doc-infxcqhz3531514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","159776"],"gpt_icon":0},{"id":"2582981337","title":"招银国际：CXO企业下半年业绩或复苏 看好中国生物制药及药明合联等","url":"https://stock-news.laohu8.com/highlight/detail?id=2582981337","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582981337?lang=zh_cn&edition=full","pubTime":"2025-11-11 14:24","pubTimestamp":1762842240,"startTime":"0","endTime":"0","summary":"招银国际发布研报称，MSCI中国医疗指数年初至今累计升幅达59.5%，跑赢MSCI中国指数24%，至近期医药板块出现回调，10月初起回落约10%，认为部分股份估值较低，仍具吸引力，看好三生制药、固生堂、巨子生物、药明合联、信达生物及中国生物制药，均予“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-11-11/doc-infwzfae7375727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","SG9999014674.SGD","BK1521","BK1515","01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","CXO","BK1141","02268","LU2488822045.USD","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD"],"gpt_icon":0},{"id":"2582823841","title":"【券商聚焦】招银国际：CXO行业有望在下半年迎来业绩修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582823841","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582823841?lang=zh_cn&edition=full","pubTime":"2025-11-10 13:30","pubTimestamp":1762752642,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2025年初至今累计上涨59.5%，跑赢MSCI中国指数24.0%。近期，医药板块有所回调，该机构认为部分低估值个股具备吸引力。叠加美国降息，CXO行业有望在2H25E迎来业绩修复。辉瑞管理层表示即将公布707的完整研发计划。此次医保谈判结果预计12月初公布。本轮集采的平均价格降幅并未公布。该机构认为仿制药仍将长期维持较低利润率水平。但该机构认为，本土市场的表现仍是重要的业绩变量。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969308","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0856984785.SGD","LU1226288253.USD","02269","LU0456846285.SGD","LU0456827905.SGD","02142","09995","LU1960683339.HKD","01877","IE00B0JY6N72.USD","01177","06160","LU1794554557.SGD","LU1152091168.USD","LU1951186391.HKD","09926","LU0348767384.USD","LU0540923850.HKD","LU1969619763.USD","LU2097828805.USD","LU1807302812.USD","BK1161","LU0516422440.USD","LU0572944931.SGD","01093","LU0634319403.HKD","BK1576","LU2242644610.SGD","LU0823426480.USD","01801","LU0348825331.USD","LU1328277881.USD","LU1770034418.SGD","02616","LU1251922891.USD","BK1521","06185","LU2097828631.EUR","LU2476274308.USD","LU0327786744.USD","09688","LU2097828714.EUR","LU2476274720.SGD","LU1993786604.SGD","CXO","LU0417516902.SGD","LU0039217434.USD","LU0417516738.SGD","IE0008368742.USD"],"gpt_icon":0},{"id":"2571142633","title":"招银国际：美国针对创新药将加征关税预期对CXO影响有限 推荐买入三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2571142633","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571142633?lang=zh_cn&edition=full","pubTime":"2025-09-30 15:56","pubTimestamp":1759219015,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，预期中美创新合作将持续，中国国内创新研发需求回暖。叠加美国降息，CXO 行业有望在下半年迎来业绩修复。而美国针对创新药将加征关税，预期对CXO影响有限。特朗普于9月25日宣布，除非制药商正在美国建设工厂，否则从10月1日开始，专利药品将面临100%的关税。由于多家跨国药企已有美国建厂计划，因此或将不受影响。推荐买入三生制药、巨子生物、药明合联、固生堂、中国生物制药、信达生物 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1593","LU2242644610.SGD","LU2097828714.EUR","BK1589","CXO","BK1583","LU0502904849.HKD","01801","LU2097828557.USD","01530","LU2097828474.EUR","SG9999014674.SGD","LU0455707207.USD","01177","IE00BZ08YR35.GBP","LU2488822045.USD","02273","BK1141","BK1207","IE00BZ08YT58.USD","02268","BK1521","02367","LU2097828805.USD","BK1574","BK1219","BK1161","LU1969619763.USD","SG9999004311.SGD","LU2097828631.EUR","LU2328871848.SGD","BK1515","IE00BZ08YS42.EUR","06978","159992"],"gpt_icon":0},{"id":"2571806873","title":"小摩：续列药明康德(02359)为CXO首选股 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2571806873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571806873?lang=zh_cn&edition=full","pubTime":"2025-09-29 13:52","pubTimestamp":1759125138,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，继续列药明康德(02359)为中国CXO行业的首选股，指出该公司是中国收入规模最大的合同研究开发与生产组织，看好其业务基本面，认为小分子CRDMO领域竞争相对温和，同时药明TIDES业务增长动力持续强劲，维持“增持”评级，目标价138港元。小摩日前参与药明康德的2025年投资者日，适逢美国总统特朗普宣布计划自10月1日起对进口品牌药及专利药征收100%关税，除非相关药厂已在美国动工兴建生产设施。小摩预期这次药品关税政策对药明康德等中国CDMO企业不会构成直接影响，因客户通常负责支付关税，而且药明康德正在扩充其美国产能，以满足客户对本地化生产的需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","603259","02359"],"gpt_icon":0},{"id":"2570105079","title":"信达证券：CXO市场景气度正在修复 CDMO布局新兴赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2570105079","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570105079?lang=zh_cn&edition=full","pubTime":"2025-09-26 13:57","pubTimestamp":1758866254,"startTime":"0","endTime":"0","summary":"受益于多肽、ADC等新分子需求旺盛，CDMO龙头普遍已经开始布局这些新兴赛道，带动相关业务实现不断高增长。信达证券主要观点如下：CXO整体供需关系改善，市场景气度正在修复需求侧：CXO行业本质上属于“卖水人”商业模式，其景气度和生物医药行业投融资高度相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","IE00B0JY6N72.USD","LU0417516738.SGD","LU0572944931.SGD","LU0039217434.USD","LU0348825331.USD","LU1794554557.SGD","BK1589","LU0516423174.USD","03759","601059","02359","LU2488822045.USD","LU0516423091.SGD","LU0348735423.USD","LU2045819591.USD","LU0823426480.USD","06821","SG9999014674.SGD","BK1141","BK4139","LU0181495838.USD","LU0516422440.USD","LU2125910500.SGD","BK1191","LU0708995583.HKD","LU1046422090.SGD","LU0856984785.SGD","LU1880383366.USD","02268","02269","LU0359201612.USD","LU0456846285.SGD","CXO","BK1576","CDMO","LU2242644610.SGD","LU0823426308.USD","LU0359202008.SGD","SG9999002463.SGD","06127","LU0307460666.USD","LU1688375341.USD","LU0052750758.USD","BK1610","LU1720050803.USD","LU0516422952.EUR","SG9999002562.SGD","LU0140636845.USD","LU0819121731.USD"],"gpt_icon":0},{"id":"2566959813","title":"浙商证券：25H1 CXO板块成长性趋势持续向好 在建工程仍在高位","url":"https://stock-news.laohu8.com/highlight/detail?id=2566959813","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566959813?lang=zh_cn&edition=full","pubTime":"2025-09-11 14:02","pubTimestamp":1757570536,"startTime":"0","endTime":"0","summary":"财务分析成长性：收入YOY趋势持续向好。截止20250908美股医疗保健行业IPO融资金额为30亿美元。2025Q2代表CXO公司资本开支有所波动，在建工程仍在高位。多数CXO公司资本开支季度绝对值基本处于小幅波动状态，整体较为平稳。在建工程仍在高位，说明CXO企业对产能扩张的预期仍偏乐观。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0276","601878"],"gpt_icon":0},{"id":"2564339650","title":"过半数A股企业上半年净利增长，CXO行业迎来复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2564339650","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564339650?lang=zh_cn&edition=full","pubTime":"2025-09-03 20:39","pubTimestamp":1756903140,"startTime":"0","endTime":"0","summary":"东方财富Choice数据显示，今年上半年，28家A股CXO企业中，有16家企业净利出现同比增长，而在上年同期，净利增长的企业仅有7家。净利增长个股数量增加与上年同期相比，今年上半年，CXO企业中，净利出现增长的企业数量大幅增加。业绩出现分化尽管行业整体回暖，但CXO行业的寒意仍未完全消散。年内股价全部上涨资本市场上，CXO个股的股价表现同样反映出行业复苏趋势。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-09-03/doc-infpfnye4307759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399300","CXO","159982"],"gpt_icon":0},{"id":"2564936355","title":"港股创新药“纯度”100%·恒生创新药ETF（159316）继续反弹1.65%，机构看好下半年达成更多的BD交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2564936355","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564936355?lang=zh_cn&edition=full","pubTime":"2025-09-03 11:20","pubTimestamp":1756869635,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"78cf524284cbf2410f3fde6e23cd85d4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06886","06160","HSTECH","163118","LU0540923850.HKD","LU1979443071.USD","IE00B5MMRT66.SGD","HSCEI","688235","CXO.AU","HTSC.UK","LU0348766576.USD","LU0417516571.SGD","LU1719994722.HKD","LU2328871848.SGD","07226","LU1794554557.SGD","BK0028","LU0417516902.SGD","09926","159316","LU1580142542.USD","000808.SH","YANG","LU0348783233.USD","688428","LU2488822045.USD","09969","159858","BK4614","LU1781817850.SGD","FDN","LU0634319403.HKD","CXO","00460","BK1564","688506","159992","LU1770034418.SGD","601688","515120","BK1574","06978","IE00B543WZ88.USD","BK1600","ONC","LU2148510915.USD","BK0188","03933"],"gpt_icon":0},{"id":"2564680180","title":"创新药指数“提纯”：CXO被剔除 影响几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2564680180","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564680180?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:19","pubTimestamp":1756811988,"startTime":"0","endTime":"0","summary":"今年以来，创新药成为大热版块，备受市场关注。作为聚焦创新药投资标的的恒生创新药指数、恒生港股通创新药指数，日前迎来新一轮调整，以“提纯”指数成分。根据调整方案，恒生创新药指数剔除7家公司，成分股数目从36只减少至29只；恒生港股通创新药指数则剔除5家公司，成分股数目从34只减少至29只。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509023502503260.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509023502503260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO"],"gpt_icon":0},{"id":"2564867231","title":"恒生创新药ETF（159316）涨2.65%，资金持续涌入！机构看好其高性价比的配置窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2564867231","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564867231?lang=zh_cn&edition=full","pubTime":"2025-09-01 11:28","pubTimestamp":1756697331,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"82902c950c26b9e099be3b2ea5e92ba0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2488822045.USD","BK1574","159316","LU2097828557.USD","600109","BK1161","BK4585","LU1969619763.USD","BK1583","BK4550","BK0201","BK1589","HSCEI","BK0276","07226","FDN","515120","YANG","BK0028","CXO.AU","BK0012","LU2097828474.EUR","LU2097828631.EUR","LU2328871848.SGD","CXO","HSTECH","LU2097828805.USD","BK0188","01801","BK7095","06978","LU2097828714.EUR","159992","BK4588","159858","BK7504","BK4614","BK0183"],"gpt_icon":0},{"id":"2563019894","title":"图解中国各行业的“周期位置”--强扩张期的光模块，出清末期的CXO等","url":"https://stock-news.laohu8.com/highlight/detail?id=2563019894","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563019894?lang=zh_cn&edition=full","pubTime":"2025-08-29 14:55","pubTimestamp":1756450520,"startTime":"0","endTime":"0","summary":"广发证券认为，基于构建的行业比较数据库，通过分析龙头公司盈利周期等财务数据，将A股各行业基本面周期划分为七个阶段：下行期、出清初期、出清中期、出清末期、回升期、扩张期、筑顶期。当前光模块等AI相关行业处于强扩张期，收入利润高增、产能扩张；CXO、IGBT等医药汽车军工上游供应链处于出清末期，供给出清、盈利触底改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3754494","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3754494","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO","CXO.AU","BK7504","BK7095"],"gpt_icon":0},{"id":"2562216471","title":"里昂：升药明生物目标价至42.6港元 料重新加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2562216471","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562216471?lang=zh_cn&edition=full","pubTime":"2025-08-25 14:55","pubTimestamp":1756104911,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，料药明生物(02269)将于2025至27年重新加速增长，将期内收入预测上调0%至4%，净利润预测上调0%至7%，毛利率将由2024年的28.5%，料提升至2027年的30.8%。该行将公司目标价由34.8港元上调至42.6港元，重申跑赢大市评级。医药合同外包服务(CXO)行业的盈利与估值对资金环境变化较敏感，该行预期美国下半年潜在减息将推动市场偏好CXO板块。相较上半年，今年下半年至明年在更有利的资金环境下，全球的生物科技公司将增加研发投入，而制药企业亦将扩大研发支出以缓解专利壁垒压力，并将持续惠及药明生物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825150909975f20fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250825150909975f20fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CXO"],"gpt_icon":0},{"id":"2561620459","title":"美国航天系统，降本增“笑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2561620459","media":"观察者网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561620459?lang=zh_cn&edition=full","pubTime":"2025-08-21 14:11","pubTimestamp":1755756713,"startTime":"0","endTime":"0","summary":"美国总统特朗普自今年初上台后，在整个联邦政府系统大刀阔斧地推进“降本增效”运动。在此过程中，与环境检测和科学研究关系极为密切的美国太空军遭受极大影响。截至2025年4月，美国太空军已裁撤14%的文职人员，大量空间科学项目被砍，节约下来的部分资金也被挪至特朗普的新计划“金色穹顶”。随着美国太空军于2019年底成立，第18太空控制中队划归美国太空军，并于2022年改名为第18太空防卫中队，编制上归属于美国太空军Space Delta 2。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8m01X4sHywe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["PSP","BK4226","MMS","BK4106","CXO"],"gpt_icon":0},{"id":"2560127698","title":"左手双抗右手ADC：药明生物与药明合联角逐CXO增长新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2560127698","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560127698?lang=zh_cn&edition=full","pubTime":"2025-08-20 15:16","pubTimestamp":1755674190,"startTime":"0","endTime":"0","summary":"截至目前，药明生物已赋能超50个分子项目，并有权益收取未来的潜在里程碑付款和销售提成。新签项目中，双抗、多抗、ADC占比超过70%。行业红利持续兑现梳理药明生物、药明合联的财报可见，双抗/多抗、ADC等不仅是两家公司核心业务特色与优势领域，更是驱动业绩持续上涨的关键增长极。其中国产双抗/多抗、被誉为“魔法导弹”的ADC药物等，正成为中国药企出海征途上的新增量引擎。事实上，ADC及更广泛生物偶联药物的爆发只是开始。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820151957a6f0a402&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820151957a6f0a402&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CXO","BK4080","ADC","BK4231"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}